以岭药业(002603) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥1,125,866,592.68, representing a year-on-year growth of 38.17%[7] - Net profit attributable to shareholders was ¥113,743,965.11, up 3.30% from the same period last year[7] - The company reported a net profit of ¥561,809,987.95 for the year-to-date, reflecting a 25.01% increase year-on-year[7] - The net profit attributable to shareholders for 2018 is expected to increase by 10% to 30%, ranging from ¥594,775.6 to ¥702,916.6[18] - Net profit attributable to the parent company was CNY 113,743,965.11, up from CNY 110,110,644.26, reflecting a growth of 3.0% year-over-year[37] - The net profit for the current period was ¥115,874,921.60, compared to ¥98,462,888.24 in the same period last year, reflecting a growth of approximately 17.4%[41] - The company achieved a total profit of ¥548,818,508.07, compared to ¥480,629,336.24 in the previous period, demonstrating overall growth in financial performance[49] Assets and Liabilities - Total assets at the end of the reporting period reached ¥8,450,991,668.10, an increase of 7.15% compared to the previous year[7] - The total assets of the company reached ¥8,450,991,668.10, an increase from ¥7,887,369,191.32 at the beginning of the period[29] - Total liabilities rose to CNY 878,303,461.45 from CNY 775,580,452.40, an increase of 13.3%[33] - The total equity attributable to shareholders reached CNY 7,572,202,404.63, up from CNY 7,110,187,472.49, indicating a growth of 6.5%[34] Cash Flow - The net cash flow from operating activities was -¥3,650,862.80, a decrease of 90.52% compared to the previous year[7] - The company's cash flow from operating activities improved significantly, with a net cash inflow of ¥184,587,701.55, a 213.07% increase year-on-year[15] - Cash flow from operating activities generated a net amount of ¥184,587,701.55, a significant recovery from a negative cash flow of -¥163,257,244.34 in the previous period[50] - Total cash inflow from operating activities was ¥2,885,801,380.03, while total cash outflow was ¥2,793,030,884.01, resulting in a net cash inflow of ¥92,770,496.02[55] Research and Development - Research and development expenses rose by 30.98% to ¥180,406,518.26 as a result of increased investment in R&D[15] - The company reported R&D expenses of CNY 57,733,861.35, compared to CNY 49,456,754.49 in the previous year, reflecting a 16.0% increase[35] - Research and development expenses increased to ¥132,336,136.42 from ¥96,742,269.54, reflecting the company's commitment to innovation[48] Shareholder Information - The total number of shareholders at the end of the reporting period was 43,181[11] - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., held 23.73% of the shares, amounting to 286,276,398 shares[11] Investment Income - Investment income increased by 69.41% to ¥20,403,102.12 due to higher returns from financial products and money market funds[15] - The company achieved an investment income of ¥5,356,541.77, slightly down from ¥5,751,895.37 in the previous period[41] Operating Costs - The company's total operating costs for the current period were ¥3,184,856,853.81, compared to ¥2,533,520,945.84 in the previous period, representing an increase of about 25.7%[44] - Sales expenses rose to ¥1,112,304,082.03 from ¥875,044,253.50, indicating increased investment in marketing and sales efforts[48]